Julia C Stingl

Summary

Affiliation: University of Ulm
Country: Germany

Publications

  1. ncbi Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
    J C Stingl
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Mol Psychiatry 18:273-87. 2013
  2. ncbi Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer
    Sumit Parmar
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Germany
    Breast Cancer Res 13:R57. 2011
  3. ncbi Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs
    J C Stingl Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Baden Wurttemberg, Germany
    Clin Pharmacol Ther 89:198-209. 2011
  4. ncbi Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population
    Julia C Stingl
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Germany
    BMC Cancer 11:360. 2011

Collaborators

  • Angela Seeringer
  • Sumit Parmar
  • J C Stingl Kirchheiner
  • Uwe Langsenlehner
  • Jurgen Brockmoller
  • Alexander Kainz
  • J Brockmoller
  • Elisabeth Haschke-Becher
  • Peter Krippl
  • Wilfried Renner
  • Ariana Huber-Wechselberger

Detail Information

Publications4

  1. ncbi Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
    J C Stingl
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany
    Mol Psychiatry 18:273-87. 2013
    ....
  2. ncbi Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer
    Sumit Parmar
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Germany
    Breast Cancer Res 13:R57. 2011
    ..The present study aimed to describe the impact of the UGT2B7(His268Tyr) polymorphism on invasive disease-free survival in breast cancer patients after epirubicin treatment...
  3. ncbi Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs
    J C Stingl Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Baden Wurttemberg, Germany
    Clin Pharmacol Ther 89:198-209. 2011
    ....
  4. ncbi Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population
    Julia C Stingl
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Germany
    BMC Cancer 11:360. 2011
    ..However, placebo-controlled trials demonstrating the efficacy of nutraceuticals for the (secondary) prevention of colorectal polyps as precursors for colorectal cancer are missing...